Investor Relations

Press Releases

14 Mar 23

Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results

New Business Strategy Focused on Precision Oncology LONDON and HONG KONG, March 14, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial results for the fourth quarter and full

02 Mar 23

Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology

LONDON and HONG KONG, March 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scientific Advisory Board (the ‘SAB’) to provide strategic input based on their scientific knowledge and

02 Feb 23

Prenetics to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

LONDON and HONG KONG, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that its management team will participate virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from

19 Jan 23

Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA

LONDON and HONG KONG, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced an executive leadership change to ensure the company realizes the full potential of its broad genetics and digital testing platform and as a

View All News

Stock Information

Press Releases

Recent Events

Featured Reports